ArticleThe Indian journal of medical research2026
Targeted metabolomic profiling of gastric cancer biopsies.
Article in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Gastric cancer, the fifth most diagnosed malignancy worldwide and seventh in India, exhibits high metabolic activity and marked heterogeneity. In this study, we performed targeted metabolomic profiling of gastric cancer biopsies obtained through esophagogastroduodenoscopy in a South Indian cohort. Methods Targeted metabolite profiling was conducted using liquid chromatography-mass spectrometry (LC-MS) analysis. Pathway enrichment and biomarker evaluation were performed using MetaboAnalyst 6.0, incorporating univariate analysis and receiver operating characteristic (ROC) curve assessment. Results LC-MS based analysis of tumour (n=25), paired normal (n=25), and normal gastric mucosa (n=3) samples revealed distinct metabolic alterations associated with gastric cancer. The metabolic profiles of tumours and paired normal tissues were similar when compared with normal mucosa, suggesting a potential field effect in gastric carcinogenesis. A total of 58 metabolites were identified, of which 44.8% comprising peptides, amino acids, and their derivatives showed marked upregulation in tumours, indicating enhanced amino acid metabolism. Elevated uracil and uridine levels suggested altered pyrimidine metabolism, reflecting increased nucleotide turnover and supporting rapid DNA/RNA synthesis. Pathway analysis highlighted modulation of arginine biosynthesis, serine-one carbon metabolism, and nucleotide metabolism in gastric cancer tissues. ROC analysis identified ornithine and citrulline as potential discriminators in gastric cancer. Interpretation and conclusions Our findings reveal differentially altered metabolites in gastric cancer that are predominantly involved in arginine, serine one-carbon, and nucleotide metabolism. Ornithine and citrulline were identified as potential diagnostic biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.